Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Neurology

Remdesivir accelerates for COVID-19 recovery; M...

Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 pat...

Apr 30, 2020

recent-pharma-news
AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

Find More
pharma news
Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial

Sage Therapeutics seeking out to save flunked depression drug  Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allost...

Find More
Dubai healthcare
Dubai: A leading and exciting pharma hotspot

The dream of the UAE government to place its capital city among the best cities in the world has led to the introduction of ‘Dubai plan 2021’, focused on transforming into a smart city through an investment of more than USD 7 Billion. Dubai’s smart city strategy includes over 100 initiatives, which aims at fosterin...

Find More

More Views & Analysis

cocaine addiction
Gene therapy might make cocaine less addictive

Cocaine- a stimulant- made from the most addictive plant - cocoa plant, is known as the most addictive substance known to be existing on the Earth, hence is abused the most. As per the annual report titled ‘Key Substance Use and Mental Health Indicators in the United States’ presented by the National Survey on Drug...

Find More

Opioid Withdrawal Syndrome
Opioid Withdrawal Syndrome Pipeline: What lies in the future for those facing withdrawal symptoms

Every time an opioid therapy is in the option for any patient to overcome the pain due to some chronic ailment, the risk of opioid abuse, misuse, or dependence always lingers at the back of mind. After termination of the opioids, the patient finds it difficult to stop the use of drugs and begins to crave for it. Th...

Find More

Pharma News
US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing

Formerly known as eptinezumab, Lundbeck’s Vyepti has received the recommendation from the US FDA for preventing migraine in adults. Estimated to affect women twice as compared to men, around 1.3billion people worldwide, and approximately 38 million people in the US are afflicted with Migraine.  With the gree...

Find More

Opioid Withdrawal Syndrome
Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates

The year 2016, around 48.5 million Americans older than 12 years, reported to be actively abusing prescription opioids or involved in illicit drug use, says CDC drug surveillance report. The toll has been increasing and is almost impossible to ignore. It is disheartening to note that between the period between 1999...

Find More

Pharma News
Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hydrogel injection

Activated immune cells responsible for improving age-related diseases  The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL-5. There has been researching going on, and the researchers at Albany Medical College discovered that if these two signalling molecules ...

Find More

pharma news
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...

Find More

Halitosis is an oral health problem caused by volatile molecules which are formed because of patholo.....

Find More

Primary Progressive Aphasia (PPA) is a rare neurological disorder that results from the damages to t.....

Find More

HIV-associated lipodystrophy (HAL), is a condition characterized by the redistribution of adipose ti.....

Find More

Xerostomia is a condition characterized by dry mouth, which is a result of a reduced or absent flow .....

Find More

Acute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes low blood oxygen......

Find More

The gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....

Find More